Evidence map›Paper›PMID 41646941›Full record

ReviewFrontiers in pharmacology2025

Astragaloside IV is a potential natural neuroprotective agent for stroke: a review.

Qiao-Li Zhang, Wen-Xiu Qin, Xiu-Juan Li, Yun-Bo Zhang, Ming Li, Jun-Feng Xu, Zhong-Nan Mao

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. International journal of molecular sciences · 2026
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Qiao-Li Zhang *Department of Rehabilitation, The Affiliated Hospital of Gansu University of Chinese Medicine, Lanzhou, Gansu, China.
Wen-Xiu Qin *Department of Acupuncture and Moxibustion, National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, China.
Xiu-Juan Li *College of Acupuncture and Massage, Gansu University of Chinese Medicine, Lanzhou, Gansu, China.
Yun-Bo ZhangCollege of Acupuncture and Massage, Gansu University of Chinese Medicine, Lanzhou, Gansu, China.
Ming LiDepartment of Rehabilitation, The Affiliated Hospital of Gansu University of Chinese Medicine, Lanzhou, Gansu, China.
Jun-Feng XuDepartment of Acupuncture and Moxibustion, National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, China.
Zhong-Nan MaoCollege of Acupuncture and Massage, Gansu University of Chinese Medicine, Lanzhou, Gansu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Stroke poses a severe threat to human health, with limited therapeutic options currently available. Astragaloside IV (AS-IV), a primary bioactive metabolite derived from Astragalus membranaceus, exhibits multifaceted pharmacological effects, including anti-inflammatory, anti-fibrotic, and antioxidative properties. This review systematically examines recent advances in AS-IV research for stroke treatment, detailing its sources, physicochemical characteristics, mechanisms of action, and therapeutic efficacy in both

Indexed as

angiogenesisapoptosisAstragaloside IVneuroprotectionoxidative stressstroke

Identifiers

PMID41646941
PMCPMC12868170

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.